NMN & NAD+ for Kidney Health (CKD): What's Proven?
Human NR trials in CKD and acute kidney injury measured metabolism, exercise and safety. None establishes NMN as a treatment that preserves kidney function.
Updated
5 min read · 11 sources
On this page
The kidney is one of the most NAD+-dependent organs in the body, and that has made NAD+ precursors — NMN, NR, and niacin/nicotinamide — a hot topic for "kidney health." The mechanistic case is genuinely strong, and the animal data is striking. But there's a hard line running through this evidence that most supplement marketing erases: nearly all the impressive results are in mice and in acute kidney injury, not in people with chronic kidney disease (CKD) — and the different NAD+ precursors do not behave the same way. Here's an honest map of what's proven, what's preclinical, and where the popular claims run ahead of the data.
Why the kidney is an NAD+ story
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
Peter MD
Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan
See Peter MDThe rationale is real. Kidney tubule cells are metabolically demanding and rely heavily on NAD+ for cellular energy and stress-defense pathways. A landmark study in Nature showed that the master metabolic regulator PGC1α drives NAD+ biosynthesis in the kidney, and that this NAD+ production protects against acute kidney injury — directly linking the organ's NAD+ supply to its resilience 1. When injury or aging depletes kidney NAD+, the tissue becomes more vulnerable. That is the engine behind every "boost NAD+ for your kidneys" claim.
Acute vs chronic — and which precursor
Swipe table to compare all columns →
| Acute kidney injury | Chronic kidney disease | |
|---|---|---|
| NMN | Protective findings in mice | Human kidney protection unproven |
| NR | Mouse findings; small human NR-plus-pterostilbene safety study | 25-person human crossover trial; no peak exercise improvement |
| Nicotinamide | Distinct B3 form | Dialysis phosphate studies; tolerability limitations |
| Established human kidney protection | Not established by these trials | Not established by these trials |
It's a compelling mechanism. But mechanism is not outcome — and as you'll see, the precursor that works in one kidney scenario can fail in another.
The animal evidence: strong, but mostly acute injury
In mice, NAD+ precursors repeatedly protect the kidney — in acute settings. NMN restored the aged kidney's lost resistance to acute kidney injury: older mice that had become susceptible to AKI were protected when given NMN, an NAD+ precursor 2. In a mouse model of diabetic kidney disease, pre-emptive short-term NMN treatment was protective as well 3. And broadening to the precursor class, NAD+ precursor supplementation prevented an inflammatory cascade (an mtRNA/RIG-I–driven response) during kidney injury in mice 4. The de novo NAD+ pathway is also how caloric restriction protects the kidney in animal models 5.
Taken together, this is a robust preclinical story: in rodents, raising kidney NAD+ protects against acute and metabolic kidney injury. The honest caveat is that none of it is a human trial, and rodent kidney metabolism doesn't always translate.
The crucial nuance: NMN, NR, and nicotinamide are not interchangeable — and acute ≠ chronic
Here's the distinction supplement copy almost never makes. The various NAD+ precursors behave differently, and acute kidney injury responds differently than chronic kidney disease.
The clearest illustration: one study directly compared NAD+ deficiency in acute versus chronic kidney disease and tested nicotinamide riboside (NR). NR was protective in acute kidney injury — it prevented the rise in urea and creatinine and reduced tubular damage. But in chronic kidney disease, NR supplementation did not prevent disease progression 6. Same precursor, opposite result, depending on whether the injury was acute or chronic.
Strength of evidence by claim
- NAD+ central to kidney resilience (mechanism)Strong evidence
PGC1α-driven NAD+ synthesis protects the kidney (Nature).
- NMN / precursors protect against acute injury (mice)Moderate evidence
Multiple rodent AKI and diabetic-nephropathy studies.
- NMN / NR slows chronic kidney disease in humansNone evidence
Small human NR studies do not establish slower CKD progression.
- Nicotinamide protects kidney function in peopleNone evidence
Human trials target phosphate control, with tolerability issues.
That matters enormously, because the people searching "NMN for kidney health" usually have chronic concerns — declining kidney function, CKD, diabetic kidney disease. The strongest protective data is in acute injury, and a negative mouse CKD result does not tell us the complete human NR story. So a result that looks like a green light ("NAD+ protects kidneys!") may not apply at all to the chronic situation most readers actually face. It also means you can't assume NMN, NR, niacin, and nicotinamide are equivalent — they enter NAD+ metabolism differently, and the kidney evidence for each is uneven. Our NR and niacin comparison explains why names within the B3 family should not be treated as equivalent.
Human NR trials in chronic kidney disease
A 2023 randomized, blinded crossover trial enrolled 25 people with CKD and eGFR below 60. Participants received NR (1,000 mg/day), CoQ10 or placebo for six weeks each. NR changed metabolic measures but did not improve peak oxygen uptake, total work or overall work efficiency versus placebo 9. These were exercise and metabolic outcomes, not a demonstration that kidney failure was prevented.
A 2025 report from this trial examined inflammatory markers, oxidative stress and cell bioenergetics. It found changes in several laboratory measures, including monocyte respiratory capacity 10. This adds mechanistic information; it is not an independent large trial showing slower CKD progression. The findings concern NR, not NMN, and cannot establish a class-wide kidney benefit.
Human acute kidney injury and dialysis studies
Human AKI research also exists. A 24-patient randomized dose-escalation study tested NR combined with pterostilbene over two days. Its focus was short-term safety and blood NAD+, rather than demonstrating kidney recovery or preventing dialysis 11. A combination product does not isolate NR's contribution and does not establish NMN efficacy.
Nicotinamide has a different evidence base. NICOREN compared it with sevelamer for phosphate control in 100 hemodialysis patients. It did not establish noninferiority and had greater tolerability problems, including low platelet counts 7. A later dialysis crossover trial also studied phosphate concentrations 8. Phosphate management in dialysis, blood NAD+ changes during AKI and preservation of kidney function in CKD are separate clinical questions.
Where the marketing outruns the evidence
So the honest summary for someone considering NMN "for the kidneys": the mechanism is real 1, the rodent data in acute injury is impressive 234, but the chronic-disease translation is unproven and inconsistent — NR did not slow progression in one mouse CKD model 6, while small human NR trials have examined different outcomes 910. Anyone marketing NMN as kidney-protective for people with CKD is extrapolating from mouse AKI studies across a gap the data hasn't closed.
A safety note that deserves emphasis: if you have reduced kidney function, do not self-prescribe high-dose B3-family supplements. The NMN safety guide separates tolerability observations in study participants from safety in people with medical conditions. The human data shows nicotinamide can cause thrombocytopenia and is poorly tolerated in dialysis patients 7, and dosing in kidney disease should be a clinician's call, not a supplement label's.
Bottom line
NAD+ is genuinely central to kidney biology, and NMN and other precursors protect the kidney impressively in mice — but almost entirely in acute injury models 1234. Human NR research now includes small CKD and AKI studies 91011, but none establishes NMN or NR as a treatment that slows CKD progression. Nicotinamide's dialysis phosphate findings address another purpose and include tolerability limitations 78. Treat "NMN for kidney health" as a preclinical hypothesis, not a proven therapy — and never substitute it for nephrology care. For how the same "great in mice, unproven in people" pattern plays out elsewhere, see NAD+ for fatty liver and the precursor comparison in NMN vs NR; for safety and dosing context, see NAD+ side effects. For the full evidence picture, start with our pillar guide to NAD+ therapy, and see where products land in the best NAD+ supplements.
Frequently asked questions
Does NMN protect your kidneys?
In mice, yes — NMN restored aged kidneys' resistance to acute kidney injury and protected in a model of diabetic kidney disease. But those are rodent studies of acute injury, not human trials. There is no robust human study showing NMN preserves kidney function or slows chronic kidney disease, so 'kidney-protective' is a preclinical hypothesis, not a proven human benefit.
Can NMN or NAD+ help chronic kidney disease (CKD)?
Small human NR studies in CKD have measured exercise tolerance, metabolic pathways and cell bioenergetics. They have not established that NR slows loss of kidney function or prevents dialysis. NMN cannot inherit a treatment claim from these NR findings or from mouse studies.
Are NMN, NR, and niacin the same for the kidney?
No. Human NR studies address CKD metabolism and short-term AKI safety, while nicotinamide studies in dialysis often address phosphate control. NMN has a separate evidence base. Results from one compound, combination or disease setting do not establish another's benefit.
Is it safe to take NMN or B3 supplements if I have kidney disease?
Be cautious and involve a clinician. Human trials show nicotinamide can cause thrombocytopenia (low platelets) and is poorly tolerated in dialysis patients. Dosing of B3-family compounds in kidney disease should be a nephrologist's decision, not something you self-prescribe from a supplement label.
References
- Tran MT, Zsengeller ZK, Berg AH, et al. (2016). PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. https://pubmed.ncbi.nlm.nih.gov/26982719/
- Guan Y, Wang SR, Huang XZ, et al. (2017). Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner. Journal of the American Society of Nephrology. https://pubmed.ncbi.nlm.nih.gov/28246130/
- Yasuda I, Hasegawa K, Sakamaki Y, et al. (2021). Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy. Journal of the American Society of Nephrology. https://pubmed.ncbi.nlm.nih.gov/33795425/
- Doke T, Mukherjee S, Mukhi D, et al. (2023). NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury. Nature Metabolism. https://pubmed.ncbi.nlm.nih.gov/36914909/
- Späth MR, Koehler FC, Hoyer-Allo KJR, et al. (2023). Organ Protection by Caloric Restriction Depends on Activation of the De Novo NAD+ Synthesis Pathway. Journal of the American Society of Nephrology. https://pubmed.ncbi.nlm.nih.gov/36758124/
- Faivre A, Katsyuba E, Verissimo T, et al. (2021). Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. Nephrology Dialysis Transplantation. https://pubmed.ncbi.nlm.nih.gov/33099633/
- Lenglet A, Liabeuf S, El Esper N, et al. (2017). Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation. https://pubmed.ncbi.nlm.nih.gov/27190329/
- Schepers L, et al. (2024). The Effect of Niacinamide Supplementation on Phosphate Concentrations in Dutch Dialysis Patients: A Randomized Crossover Trial. Journal of Renal Nutrition. https://pubmed.ncbi.nlm.nih.gov/38492684/
- Ahmadi A, Begue G, Valencia AP, et al. (2023). Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight. https://pubmed.ncbi.nlm.nih.gov/37159264/
- Ahmadi A, Valencia AP, Begue G, et al. (2025). A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in CKD. Clinical Journal of the American Society of Nephrology. https://pubmed.ncbi.nlm.nih.gov/39847432/
- Simic P, Vela Parada XF, Parikh SM, et al. (2020). Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. BMC Nephrology. https://pubmed.ncbi.nlm.nih.gov/32791973/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NAD+ & NMN for Eye Health (Glaucoma, AMD): The Evidence
Nicotinamide glaucoma trials show short-term retinal-function signals, not proven protection from blindness. Review the endpoints, liver risks and NMN evidence.
ReadNMN and Thyroid Health: TSH, Hashimoto’s and Test Interference
Does NMN affect thyroid health? Separate hormone-study claims, biotin test interference and levothyroxine questions from proven treatment.
ReadNMN for Diabetes: Insulin Sensitivity and Blood Sugar Evidence
What human NMN studies show about insulin sensitivity, glucose and HbA1c—and why a prediabetes signal is not a diabetes treatment.
ReadNMN vs NR: What the Human Trials Show
NMN and NR both raise NAD+ — but how do their human trials compare on insulin sensitivity, walking, sleep, cognition, and safety?
ReadNMN for Fertility and Egg Quality: What the Evidence Shows
NMN fertility research includes human egg-culture studies. Review the findings and why oral treatment and live-birth benefits remain unproven.
ReadCan You Take NMN with Metformin? Interaction Evidence
NMN with metformin has limited direct human evidence. What the studies establish about safety, proposed synergy, exercise and medication timing.
Read